N-glycosylation augmentation of the cystic fibrosis epithelium improves Pseudomonas aeruginosa clearance

American Journal of Respiratory Cell and Molecular Biology

Volumn 44, Issue 6, 2011, Pages 824-830

  Martino, Ashley T ^a   Mueller, Christian ^b   Braag, Sofia ^b   Cruz, Pedro E ^a   Campbell Thompson, Martha ^a   Jin, Shouguang ^a   Flotte, Terence R ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Bacterial clearance; Cystic fibrosis; Gene therapy; N glycosylation

Indexed keywords

MANNOSE PHOSPHATE ISOMERASE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL LOAD; CYSTIC FIBROSIS; DOWN REGULATION; GLYCOSYLATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; OROPHARYNX; PSEUDOMONAS AERUGINOSA; TRACHEA;

ANIMALS; CELL LINE; CELL SEPARATION; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIUM; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE THERAPY; GLYCOSYLATION; HUMANS; INFLAMMATION; MANNOSE; MANNOSE-6-PHOSPHATE ISOMERASE; MICE; PSEUDOMONAS AERUGINOSA;

BACTERIA (MICROORGANISMS); MUS; PSEUDOMONAS AERUGINOSA;

EID: 80051560823     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0285OC     Document Type: Article

References (49)

1. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991;4:35-51. (Pubitemid 21920386)
2. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci USA 2000;97:8822-8828. (Pubitemid 30626632)
3. Dinwiddie R. Pathogenesis of lung disease in cystic fibrosis. Respiration 2000;67:3-8. (Pubitemid 30114156)
4. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest 1999;103:303-307. (Pubitemid 29069978)
5. Welsh MJ, Smith AE. Cystic fibrosis. Sci Am 1995;273:52-59.
6. Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ 2007;335:1255-1259.
7. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007;58:157-170. (Pubitemid 46706507)
8. Davies JC. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence. Paediatr Respir Rev 2002;3:128-134. (Pubitemid 35331506)
9. Gomez MI, Prince A. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr Opin Pharmacol 2007;7:244-251. (Pubitemid 46731196)
10. Baum GL. Enhancing mucociliary clearance. Chest 1996;110:876. (Pubitemid 26347596)
11. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997;94:12088-12093. (Pubitemid 27467847)
12. Bryan R, Kube D, Perez A, Davis P, Prince A. Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells. Am J Respir Cell Mol Biol 1998;19:269-277. (Pubitemid 128354190)
13. Reiniger N, Lee MM, Coleman FT, Ray C, Golan DE, Pier GB. Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor. Infect Immun 2007;75:1598-1608. (Pubitemid 46559423)
14. Muir A, Soong G, Sokol S, Reddy B, Gomez MI, Van Heeckeren A, Prince A. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 2004;30:777-783. (Pubitemid 38736900)
15. Scanlin TF, Glick MC. Terminal glycosylation in cystic fibrosis. Biochim Biophys Acta 1999;1455:241-253. (Pubitemid 29435992)
16. Rhim AD, Stoykova LI, Trindade AJ, Glick MC, Scanlin TF. Altered terminal glycosylation and the pathophysiology of cf lung disease. J Cyst Fibros 2004;3:95-96. (Pubitemid 40045576)
17. Roussel P. Airway glycoconjugates and cystic fibrosis. Glycoconj J 2001;18:645-647. (Pubitemid 35398671)
18. Kube D, Adams L, Perez A, Davis PB. Terminal sialylation is altered in airway cells with impaired CFTR-mediated chloride transport. Am J Physiol Lung Cell Mol Physiol 2001;280:L482-L492.
19. Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 1995;92:3019-3023.
20. Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest 1993;92:1875-1880. (Pubitemid 23304555)
21. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR, Goldberg JB. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996;271:64-67. (Pubitemid 26033276)
22. Pier GB, Grout M, Zaidi TS, Goldberg JB. How mutant CFTR may contribute to Pseudomonas aeruginosa infection in cystic fibrosis. Am J Respir Crit Care Med 1996;154:S175-S182.
23. Cannon CL, KowalskiMP, Stopak KS, Pier GB. Pseudomonas aeruginosa-induced apoptosis is defective in respiratory epithelial cells expressing mutant cystic fibrosis transmembrane conductance regulator. Am J Respir Cell Mol Biol 2003;29:188-197. (Pubitemid 36936646)
24. Yu H, Zeidan YH, Wu BX, Jenkins RW, Flotte TR, Hannun YA, Virella-Lowell I. Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis. Am J Respir Cell Mol Biol 2009;41:367-375.
25. Bajmoczi M, Gadjeva M, Alper SL, Pier GB, Golan DE. Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa. Am J Physiol Cell Physiol 2009;297:C263-C277.
26. Virella-Lowell I, Herlihy JD, Liu B, Lopez C, Cruz P, Muller C, Baker HV, Flotte TR. Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell line. Mol Ther 2004;10:562-573. (Pubitemid 39186117)
27. Larsson A, Flodin M, Kollberg H. Increased serum concentrations of carbohydrate-deficient transferrin (CDT) in patients with cystic fibrosis. Ups J Med Sci 1998;103:231-236. (Pubitemid 128523951)
28. Kjaergaard S. Congenital disorders of glycosylation type IA and IB: genetic, biochemical and clinical studies. DanMed Bull 2004;51:350-363. (Pubitemid 41519090)
29. Westphal V, Kjaergaard S, Davis JA, Peterson SM, Skovby F, Freeze HH. Genetic and metabolic analysis of the first adult with congenital disorder of glycosylation type IB: long-term outcome and effects of mannose supplementation. Mol Genet Metab 2001;73:77-85. (Pubitemid 34177627)
30. Coleman FT, Mueschenborn S, Meluleni G, Ray C, Carey VJ, Vargas SO, Cannon CL, Ausubel FM, Pier GB. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc Natl Acad Sci USA 2003;100:1949-1954. (Pubitemid 36254554)
31. Virella-Lowell I, Zusman B, Foust K, Loiler S, Conlon T, Song S, Chesnut KA, Ferkol T, Flotte TR. Enhancing RAAV vector expression in the lung. J Gene Med 2005;7:842-850. (Pubitemid 41015532)
32. Sirninger J, Muller C, Braag S, Tang Q, Yue H, Detrisac C, Ferkol T, Guggino WB, Flotte TR. Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther 2004;15:832-841. (Pubitemid 39244838)
33. Cruz PE, Mueller C, Cossette TL, Golant A, Tang Q, Beattie SG, Brantly M, Campbell-Thompson M, Blomenkamp KS, Teckman JH, et al. In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest 2007; 87:893-902. (Pubitemid 47267814)
34. Singh AP, Chauhan SC, Andrianifahanana M, Moniaux N, Meza JL, Copin MC, van Seuningen I, Hollingsworth MA, Aubert JP, Batra SK. Muc4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms. Oncogene 2007;26:30-41. (Pubitemid 46067329)
35. Bloemberg GV, O'Toole GA, Lugtenberg BJ, Kolter R. Green fluorescent protein as a marker for Pseudomonas spp. Appl Environ Microbiol 1997;63:4543-4551. (Pubitemid 27485787)
36. Hoffmann N, Rasmussen TB, Jensen PO, Stub C, Hentzer M, Molin S, Ciofu O, Givskov M, Johansen HK, Hoiby N. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 2005;73:2504-2514. (Pubitemid 40470854)
37. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 1994;266:1705-1708.
38. Mueller C, Torrez D, Braag S, Martino A, Clarke T, Campbell-Thompson M, Flotte TR. Partial correction of the CFTR-dependent ABPA mouse model with recombinant adeno-associated virus gene transfer of truncated CFTR gene. J Gene Med 2008;10:51-60.
39. Rodriguez-Pineiro AM, Ayude D, Rodriguez-Berrocal FJ, Paez de la Cadena M. Concanavalin A chromatography coupled to two-dimensional gel electrophoresis improves protein expression studies of the serum proteome. J Chromatogr B Analyt Technol Biomed Life Sci 2004;803:337-343.
40. Hughes RC, Mills G. Analysis by lectin affinity chromatography of Nlinked glycans of BHK cells and ricin-resistant mutants. Biochem J 1983;211:575-587. (Pubitemid 13103188)
41. Pilobello KT, Slawek DE, Mahal LK. A ratiometric lectin microarray approach to analysis of the dynamic mammalian glycome. Proc Natl Acad Sci USA 2007;104:11534-11539. (Pubitemid 47175047)
42. Varki A. Essentials of glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
43. Moore JS, Kulhavy R, Tomana M, Moldoveanu Z, Suzuki H, Brown R, Hall S, Kilian M, Poulsen K, Mestecky J, et al. Reactivities of Nacetylgalactosamine- specific lectins with human IgA1 proteins. Mol Immunol 2007;44:2598-2604. (Pubitemid 46240321)
44. Hoyle BD, Williams LJ, Costerton JW. Production of mucoid exopolysaccharide during development of Pseudomonas aeruginosa biofilms. Infect Immun 1993;61:777-780. (Pubitemid 23030874)
45. Schroeder TH, Zaidi T, Pier GB. Lack of adherence of clinical isolates of Pseudomonas aeruginosa to asialo-GM(1) on epithelial cells. Infect Immun 2001;69:719-729. (Pubitemid 32109531)
46. Hutchison ML, Govan JR. Pathogenicity of microbes associated with cystic fibrosis. Microbes Infect 1999;1:1005-1014.
47. Schroeder TH, Reiniger N, Meluleni G, Grout M, Coleman FT, Pier GB. Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. J Immunol 2001;166:7410-7418. (Pubitemid 32525618)
48. Ferlinz K, Hurwitz R, Moczall H, Lansmann S, Schuchman EH, Sandhoff K. Functional characterization of the N-glycosylation sites of human acid sphingomyelinase by site-directed mutagenesis. Eur J Biochem 1997;243:511-517. (Pubitemid 27060441)
49. Su Y, Royle L, Radcliffe CM, Harvey DJ, Dwek RA, Martinez-Pomares L, Rudd PM. Detailed N-glycan analysis of mannose receptor purified from murine spleen indicates tissue specific sialylation. Biochem Biophys Res Commun 2009;384:436-443.